このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

非集中治療室病棟に入院している65歳以上の患者における市中肺炎に対するアモキシシリン単独とアモキシシリン/クラブラン酸塩の比較 (CAPTAIN)

2026年11月16日 更新者:Nantes University Hospital

非集中治療室病棟に入院している65歳以上の患者における市中肺炎に対するアモキシシリン単独とアモキシシリン/クラブラン酸塩の比較:非劣性ランダム化比較試験

Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions.

In the majority of the studies of CAP, there is a large proportion of cases with no pathogen identified. Thus, the choice of the empirical antibiotic depends on the most likely pathogen, individual risk factors, comorbidities, and allergies.

Patients aged 65 years or older are often treated with amoxicillin/clavulanate or with another broad-spectrum antibiotic (third-generation cephalosporins, antipneumococcal fluoroquinolone). However, broad-spectrum antibiotic prescription in CAP is debated and concerns exist about side-effects and selective pressure for resistance. Due to lack of head-to-head antibiotic comparisons, a recent Cochrane review concluded that current evidence from Randomized Clinical Trials (RCTs) is insufficient to make evidence-based recommendations for the choice for antibiotic to be used, highlighting an important evidence gap.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Thus, the goal of the proposed trial is to compare clinical efficacy and safety of two CAP antimicrobial treatments, amoxicillin and amoxicillin/clavulanate, in patients aged 65 years or older and hospitalized in a non-intensive care unit (ICU) ward. The CAPTAIN study will be a multi-center, randomized, open, non-inferiority trial comparing clinical efficacy at Day 30 among patients ≥65 years of age, and hospitalized in a non-ICU ward, treated with narrow-spectrum (amoxicillin) versus broad-spectrum (amoxicillin/clavulanate) antimicrobial therapy for CAP. This will be a pivotal clinical trial that will provide evidence to inform CAP treatment guidelines.

研究の種類

介入

入学 (推定)

326

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Angers、フランス
      • Angers、フランス
      • Bobigny、フランス
      • Brest、フランス
      • La Roche-sur-Yon、フランス
      • La Tronche、フランス
      • Marseille、フランス
        • 募集
        • Assistance Publique Hopitaux De Marseille
        • コンタクト:
      • Nantes、フランス
        • 募集
        • CHU de Nantes
        • 主任研究者:
          • Emmanuel Montassier, MD
        • コンタクト:
      • Périgueux、フランス
      • Saint-Nazaire、フランス、44600
        • 募集
        • CH Saint-Nazaire
        • コンタクト:
        • 主任研究者:
          • Matthieu THIBAULT, Doctor
        • コンタクト:
      • Toulouse、フランス
      • Toulouse、フランス
        • 募集
        • CHRU TOULOUSE - Hôpital Rangueuil
        • コンタクト:
      • Vannes、フランス

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

65年歳以上 (高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Patient aged 65 years or older with or without comorbidities defined by chronic diseases in immunocompetent patients,
  2. Patient admitted to the hospital for a CAP defined by at least two clinical signs of pneumonia (cough, sputum production, dyspnea, tachypnea, or pleuritic pain, abnormal lung auscultatory sounds, fever (temperature > 38°C) or hypothermia (<36°C)), and had radiological evidence of a new infiltrate confirming pneumonia
  3. Patient understanding oral and written French
  4. Written informed consent obtained from patient prior to participation in the study (if the patient is unable to express in writing: consent by a trusted person).
  5. Patients should be able to call and to answer to a phone call or to be with a relative who can help him to call or to answer questions notably raised by a medical staff belonging to the investigational site

Exclusion Criteria:

  1. Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency, ICU admission)
  2. Patient requiring ICU admission,
  3. Estimated Glomerular Filtration Rate < 30 ml/min,
  4. Known immunosuppression (asplenia, neutropenia, agammaglobulinemia, transplant, myeloma, lymphoma, known HIV and CD4<200/mm3),
  5. Exacerbation of chronic obstructive pulmonary disease,
  6. Life-threatening state expected to lead to possible imminent death,
  7. Suspected atypical bacteria requiring combined antibiotics therapy,
  8. Legionella suspected,
  9. Subjects with clinical or epidemiological environment leading to suspect a healthcare associated pneumonia with antibiotic resistant pathogen (including long-term care facility)
  10. Patient known to be colonized with Pseudomonas aeruginosa or Enterobacteriaceae in the respiratory tract,
  11. Suspicion of aspiration pneumonia,
  12. Administration of any antibiotic treatment for more than 24 hours before inclusion,
  13. History of jaundice/hepatic impairment associated with amoxicillin/clavulanate acid,
  14. History of bacterial pneumonia less than 1 month prior to study inclusion
  15. History of hypersensitivity or allergy to beta-lactam or to any excipients included in study antibiotics,
  16. Subject without health insurance,
  17. Subject without home address or difficulty in terms of follow-up (vacation, job transfer, geographical distance, lack of motivation),
  18. Patient under judicial protection,
  19. Diagnosis confirmed of SAR-Cov2 infection (PCR Test, covid antigen rapid test, chest computed tomography (CT) scan),
  20. Participation to another interventional study and having an exclusion period that is still in force during the screening phase or expected participation to another interventional study during participation to the CAPTAIN study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Amoxicillin

Amoxicillin is an antibiotic treatment approved in France and in many countries.

The investigational medicinal products (IMPs) are:

- Amoxicillin capsules : Formulated as a 500 mg capsules for PO administration (commercially available). Description in IMP file.

Amoxicillin capsules contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15- 25°C.

- Amoxicillin IV vials : Formulated as a 1000 mg vial for IV administration (commercially available). Description in IMP file.

Amoxicillin IV vials contain compendial excipient listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C.

Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.

Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily).

Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)

他の名前:
  • 治験薬
アクティブコンパレータ:Amoxicillin/clavulanate

Amoxicillin/clavulanate is recommended by French and European guidelines for the treatment of patients aged 65 years or older, and hospitalized in a non-ICU ward, as reported above.

The active comparators (IMPs) are:

- Amoxicillin/clavulanate tablets: Formulated as a tablet for PO administration (commercially available). Description in IMP file. Tablets contain 500 mg of amoxicillin trihydrate and 62.5 mg of clavulanate. Amoxicillin/clavulanate tablets contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C.

- Amoxicillin/clavulanate vials Vials contain 1000 mg of amoxicillin and 200 mg of clavulanate. Description in IMP file.

Amoxicillin/clavulanate vials contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C

Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.

Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)

他の名前:
  • アクティブ比較薬

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Non-inferiority
時間枠:Day 30 after inclusion (=Day 1)

To investigate non-inferiority in terms of clinical efficacy among patients aged 65 years or older, hospitalized in a non-ICU ward for a CAP, and treated with narrow-spectrum (amoxicillin) versus broad-spectrum (amoxicillin/clavulanate) antimicrobial therapy, at Day 30 since hospital admission. To answer this question, clinical success rate at Day 30 since admission, defined as survival after completion of antibiotic treatment course, resolution of signs and symptoms of the infection (cough, purulent sputum production, dyspnea, or pleuritic chest pain) present at baseline with no new symptoms or complications attributable to CAP and no need for further antibacterial therapy will be determined

Day 30 after inclusion (=Day 1)

二次結果の測定

結果測定
メジャーの説明
時間枠
入院期間を調べるため
時間枠:封入後30日以内(=1日目)
封入後30日以内(=1日目)
Rates of early clinical response
時間枠:Day 3 after inclusion (=Day 1)

Early clinical response will be defined as survival with improvement of one or more levels relative to baseline in two or more symptoms of CAP and no worsening of one or more levels in other symptoms of community-acquired bacterial pneumonia, without receipt of rescue antibacterial therapy

Day 3 after inclusion (=Day 1)
Clinical cure after the end of treatment
時間枠:Within 30 days after inclusion (=Day 1) compared to baseline

The proposed endpoint of clinical cure after the end of treatment is defined as resolution in relevant signs and symptoms reported at baseline, no worsening of symptoms, and no change in antimicrobial regimen

Within 30 days after inclusion (=Day 1) compared to baseline
To investigate total duration of antibiotic treatment, i.e., the total number of days with antibiotics during the Day 30 follow-up after hospital admission
時間枠:Day 30 after inclusion (=Day 1)

Days taking antibiotics from the first dose until the interruption of any antibiotic treatment during hospitalization and at late follow-up at Day 30 after hospital admission (to identify the use of any other antibiotic after hospital discharge defined as no IV, regain of autonomy identical to baseline, good clinical response and favorable evolution following initiation of antibiotics, other criteria left at the discretion of the investigators according to centers' practices)

Day 30 after inclusion (=Day 1)
To investigate all-cause mortality at Day 30 after hospital admission
時間枠:Day 30 after inclusion (=Day 1)

All-cause mortality at Day 30 after hospital admission

Day 30 after inclusion (=Day 1)
To investigate the rate of polymerase chain reaction (PCR)-positive Clostridium difficile among patients with diarrhea
時間枠:Within 30 days after inclusion (=Day 1)

Number of positive polymerase chain reaction (PCR)-positive Clostridium difficile among patients with diarrhea

Within 30 days after inclusion (=Day 1)
To investigate in-hospital mortality
時間枠:Within 30 days after inclusion (=Day 1)

Number of deaths during hospitalization

Within 30 days after inclusion (=Day 1)
To investigate ICU transfer during the Day 30 follow-up
時間枠:Day 30 after inclusion (=Day 1)

Number of patients transferred to the ICU during the Day 30 follow-up

Day 30 after inclusion (=Day 1)
To investigate CAP recurrence and hospital readmissions up to day 30 from hospital admission
時間枠:Day 30 after inclusion (=Day 1)

Number of hospital readmissions and CAP recurrence up to day 30 from hospital admission

Day 30 after inclusion (=Day 1)
To investigate adverse events attributable to antibiotics up to day 30 from hospital admission
時間枠:Day 30 after inclusion (=Day 1)

Number of adverse events attributable to antibiotics and number of days with adverse events up to day 30 from hospital admission

Day 30 after inclusion (=Day 1)
To investigate compliance with the antibiotic treatment
時間枠:Within 7 days after inclusion (=Day 1)

Number of days of antibiotic treatment taken

Within 7 days after inclusion (=Day 1)
Analysis of sensitivity todiscordance
時間枠:Within 30 days after inclusion (=Day 1)

To investigate the agreement between the early clinical response endpoint and the investigator's clinical judgment: the agreement between early clinical response (main endpoint) and the investigator's clinical judgement (clinical success or clinical failure) will be assessed

Within 30 days after inclusion (=Day 1)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Frederic BALEN, Doctor、Toulouse UH
  • 主任研究者:Guillaume MARTIN-BLONDEL, Doctor、Toulouse UH
  • 主任研究者:Perrine DUMANOIR, Doctor、Grenoble Hospital
  • 主任研究者:VIGLINO Damien, Doctor、Grenoble Hospital
  • 主任研究者:Alexandrine VIDAL, Doctor、Perigueux Hospital
  • 主任研究者:Delphine PLARD, Doctor、Angers UH
  • 主任研究者:Rafaël MAHIEU, Doctor、Angers UH
  • 主任研究者:Anne-Laure FERAL-PIERSSENS, Doctor、Avicenne AP-HP
  • 主任研究者:Frederic MECHAI, Doctor、Avicenne AP-HP
  • 主任研究者:Aurelie DAUMAS, Professor、Marseille Timone Hospital
  • 主任研究者:Pierre BARSI, Doctor、Vannes Hospital Bretagne Atlantic
  • 主任研究者:Rozenn LE BERRE, Doctor、Brest Hospital
  • 主任研究者:Sylvain JAFFUEL, Doctor、Brest Hospital
  • 主任研究者:Xavier DUBUCS, Doctor、Toulouse UH
  • 主任研究者:Matthieu THIBAULT, Doctor、Saint-Nazaire Hospital
  • 主任研究者:BOISSEAU Dorothée, Doctor、Saint-Nazaire Hospital
  • 主任研究者:Dominique MERRIEN, Doctor、Centre Hospitalier Departemental Vendee
  • 主任研究者:Sylvain LE GENTIL, Doctor、Centre Hospitalier Departemental Vendee

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年4月25日

一次修了 (推定)

2027年5月25日

研究の完了 (推定)

2027年5月25日

試験登録日

最初に提出

2024年1月10日

QC基準を満たした最初の提出物

2024年1月19日

最初の投稿 (実際)

2024年1月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • RC20_0015

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。